Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma

Conditions:   Metastatic Solid Tumors;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Non-small Cell Lung Cancer;   Melanoma;   Head and Neck Squamous Cell Carcinoma;   Gastric Adenocarcinoma;   Renal Cell Carcinoma;   Urothelial Carcinoma;   Esophageal Adenocarcinoma Intervention:   Drug: INBRX-105 - PDL1x41BB antibody Sponsor:   Inhibrx, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials